Developing differentiated therapies that can improve the health of patients with liver and gastrointestinal (GI) diseases

NASH is expected to become the leading cause for liver transplants in the United States.

Inflammatory bowel disease is increasing in prevalence worldwide

Metacrine is building a pipeline of potential best-in-class FXR agonist therapies for NASH and other GI diseases

Our Company

We are a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and GI diseases.

Latest News

September 09, 2021

Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash

September 08, 2021

Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021

Programs

Our most advanced program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases.